Articles

Multimodality treatment approach for rectal cancer

BJMO - volume 14, issue 7, november 2020

K. Papadimitriou MD, PhD, M. Peeters MD, PhD, M. Rasschaert MD, PhD, J. Van den Brande MD, H. Prenen MD, PhD

SUMMARY

Rectal cancer treatment constitutes a complex exercise. With the exception of very early and metastatic disease were surgery and palliative chemotherapy are respectively the backbone treatment modalities, the optimal treatment strategy for rectal cancer remains a subject of active debate. Different therapeutic options, including local and systemic approaches like different surgical techniques, radiation therapy, chemoradiotherapy and chemotherapy in different sequences and settings are commonly combined in clinical practice. This multimodal treatment strategy improved survival and reduced local recurrence, but the optimal way to combine the different modalities represents a subject of active research. In the coming paragraphs we attempt to answer some of the most important questions, in our opinion, regarding multimodality treatment approach for rectal cancer through a systematic review of the literature.

(BELG J MED ONCOL 2020;14(7):311-20)

Read more

Highlights in digestive oncology

BJMO - volume 13, issue 8, december 2019

K. Papadimitriou MD, PhD, M. Peeters MD, PhD, H. Prenen MD, PhD

This report will focus on some of the key studies in the field of digestive oncology, presented during the 2019 annual ESMO meeting. During the congress, many studies were presented from early phase I to large phase III trials. Different approaches to activate the immune system against tumours as well as PARP and CDK4/6 inhibitors were once more at the centre of interest for different types of cancer and settings.

Read more

Adjuvant chemotherapy of colon cancer: 3 versus 6 months

BJMO - volume 13, issue 6, october 2019

C. Debeuckelaere MD, L. Triest MD, T. Vandamme MD, PhD, B. Van den Heuvel MD, K. Papadimitriou MD, PhD, M. Rasschaert MD, PhD, H. Prenen MD, PhD, M. Peeters MD, PhD

Summary

For over a decade, oxaliplatin-based adjuvant chemotherapy has been the gold standard for resected early colon cancer. Oxaliplatin is known to cause polyneuropathy, which affects quality of life dramatically. In recent years, there has not been any progress in the development of novel agents to replace oxaliplatin as adjuvant therapy. Consequently, there is a growing interest to investigate whether a shorter course of chemotherapy is sufficient. This article will discuss the history of adjuvant treatment in early-resected colon cancer, the toxicity of oxaliplatin, the results from the IDEA meta-analysis and future prospects.

(BELG J MED ONCOL 2019;13(6):234–239)

Read more

Highlights in gastro-intestinal oncology

BJMO - volume 12, issue 8, december 2018

B. Van den Heuvel MD, M. Rasschaert MD, PhD, L. Triest MD, C. Debeuckelaere MD, F. Couturier , K. Papadimitriou MD, PhD, H. Prenen MD, PhD, M. Peeters MD, PhD

Although none of the submitted abstracts in the field of gastro-intestinal oncology reached the presidential sessions of ESMO 2018, some practice-changing and promising data were presented especially in the field of immunotherapy. This report summarises the highlights in the field of colorectal, anal and upper digestive tract cancer.

Read more

Highlights in gastro-intestinal cancer

BJMO - volume 12, issue 4, august 2018

M. Rasschaert MD, PhD, L. Triest MD, J. Van den Brande MD, K. Papadimitriou MD, PhD, H. Prenen MD, PhD, M. Peeters MD, PhD

The 2018 annual meeting of the American Society of Oncology (ASCO) was once more hosted in Chicago. Over 40,000 oncologists attended this years’ convention. This report will summarize the highlights from the gastro-intestinal cancer sessions at the meeting.

Read more

Highlights in gastrointestinal oncology

BJMO - volume 11, issue 7, november 2017

L. Triest MD, K. Papadimitriou MD, PhD, M. Rasschaert MD, PhD, J. Van den Brande MD, M. Peeters MD, PhD

ESMO 2017 featured the presentation of several practice changing data in the field of gastrointestinal (GI) cancer. The first part of this report will summarize the key data presented in the field of gastric cancer, gastroesophageal junction (GEJ), biliary, gallbladder, biliary, pancreatic and hepatocellular cancer. In the second part, the focus is turned to colorectal cancer.

(BELG J ONCOL 2017;11(7):340–348)

Read more

Highlights in gastrointestinal cancers

BJMO - volume 11, issue 4, september 2017

K. Papadimitriou MD, PhD, M. Rasschaert MD, PhD, J. Van den Brande MD, M. Peeters MD, PhD

The 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) took place once more in Chicago from June 2 to 6, bringing together more than 30,000 oncology professionals from around the world. This year’s meeting theme is “Making a Difference in Cancer Care with You.” Studies spanning the spectrum of GI cancer prevention and care, from new standards of care to immunotherapy and precision medicine, will be highlighted.

Read more